Quote this publication Share Print

HUMIRA (adalimumab), anti-TNFα immunosuppressant

OPHTHALMOLOGY - New indication
Opinions on drugs - Posted on Dec 18 2018

Reason for request

Extension of indication

In combination with methotrexate, moderate clinical benefit and minor clinical improvement in the treatment of non-infectious chronic anterior uveitis associated with juvenile idiopathic arthritis in children (2 to 17 years), in cases of insufficient response or intolerance to conventional treatment or for whom conventional treatment is unsuitable.

 

  • HUMIRA has MA for the treatment of non-infectious chronic anterior uveitis in children from 2 years and adolescents in cases of insufficient response or intolerance to conventional treatment or for whom conventional treatment is unsuitable.

  • Its efficacy has been demonstrated versus placebo in a restricted MA population, in patients with uveitis associated with juvenile idiopathic uveitis after corticosteroid failure and in combination with methotrexate

  • The clinical improvement is minor, particularly due to uncertainties in respect of the effect size due to the methodological bias and weaknesses of the studies and the lack of long-term data.

 


Clinical Benefit

Moderate

-

Insufficient

Clinical Added Value

minor

-